Indinavir plasma concentrations and resistance mutations in patients experiencing early virological failure |
| |
Authors: | González de Requena Daniel Gallego Oscar de Mendoza Carmen Corral Angélica Jiménez-Nácher Inmaculada Soriano Vincent |
| |
Affiliation: | Pharmacology Unit, Hospital Carlos III, Instituto de Salud Carlos III, 28035 Madrid, Spain. |
| |
Abstract: | Virological failure under protease inhibitor (PI)-based antiretroviral regimens is often not explained by the selection of resistance mutations. The role of low indinavir (IDV) plasma levels in treatment failure was assessed in 46 subjects experiencing early virological failure to a first-line IDV-containing triple combination. Overall, 69% of patients showed subtherapeutic IDV plasma levels (it was not detected at all in 75% of them). Subjects with detectable but suboptimal IDV levels developed more IDV resistance mutations. Thus, drug monitoring may be useful to assess treatment adherence and risk of drug resistance in early virological failures. This information may be crucial for choosing the most appropriate rescue intervention. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|